Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Mar;30(3):277-288.
doi: 10.1007/s11655-023-3611-6. Epub 2023 Dec 7.

Research Advance of Chinese Medicine in Treating Atherosclerosis: Focus on Lipoprotein-Associated Phospholipase A2

Lu-Ming Wang  1 , Wen-Lan Zhang  1 , Nuan Lyu  1 , Yan-Rong Suo  2 , Lin Yang  1 , Bin Yu  3 , Xi-Juan Jiang  1
Affiliations
Review

Research Advance of Chinese Medicine in Treating Atherosclerosis: Focus on Lipoprotein-Associated Phospholipase A2

Lu-Ming Wang et al. Chin J Integr Med. 2024 Mar.

Abstract

As a serious cardiovascular disease, atherosclerosis (AS) causes chronic inflammation and oxidative stress in the body and poses a threat to human health. Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a member of the phospholipase A2 (PLA2) family, and its elevated levels have been shown to contribute to AS. Lp-PLA2 is closely related to a variety of lipoproteins, and its role in promoting inflammatory responses and oxidative stress in AS is mainly achieved by hydrolyzing oxidized phosphatidylcholine (oxPC) to produce lysophosphatidylcholine (lysoPC). Moreover, macrophage apoptosis within plaque is promoted by localized Lp-PLA2 which also promotes plaque instability. This paper reviews those researches of Chinese medicine in treating AS via reducing Lp-PLA2 levels to guide future experimental studies and clinical applications related to AS.

Keywords: Chinese medicine; apoptosis; atherosclerosis; inflammation; lipoprotein-associated phospholipase A2; oxidative stress.

PubMed Disclaimer

References

    1. Alexandru N, Andrei E, Safciuc F, et al. Intravenous administration of allogenic cell-derived microvesicles of healthy origins defends against atherosclerotic cardiovascular disease development by a direct action on endothelial progenitor cells. Cells 2020;9:423. - PubMed - PMC - DOI
    1. Cardiovascular diseases. Accessed October 10, 2022. Available at https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1
    1. Wang H, Guo Y, Lu H, et al. Kruppel-like factor 14 deletion in myeloid cells accelerates atherosclerotic lesion development. Cardiovasc Res 2022;118:475–488. - PubMed - DOI
    1. Xia X, Li X, Xie F, et al. Non-targeted metabonomic analysis of plasma in patients with atherosclerosis by liquid chromatographymass spectrometry. Ann Transl Med 2022;10:133. - PubMed - PMC - DOI
    1. Lu L, Qin Y, Chen C, et al. The atheroprotective roles of Heart-Protecting Musk Pills against atherosclerosis development in apolipoprotein E-deficient mice. Ann Transl Med 2019;7:714. - PubMed - PMC - DOI

Substances

LinkOut - more resources